Safety of ALK Ragweed Tablet

Phase 1

Completed

• Conditions: Allergy

• Registration Number: NCT00330083
• Lead Sponsor: ALK-Abelló A/S

Brief Summary

This trial is performed to assess whether ALK Ragweed Tablet is safe to use in adults

Detailed Description

Not available

Study Timeline

• Study Start: 2006-05
• Study First Submitted: 2006-05-23
• Study First Submitted QC: 2006-05-23
• Study First Posted: 2006-05-25
• Status Verified: 2007-09
• Last Update Submitted: 2007-09-20
• Last Update Posted: 2007-09-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

• Ragweed pollen induced rhinoconjunctivitis
• Adults of either sex (18-50 years of age)
• Positive skin prick test to ragweed

Exclusion Criteria

• Previous treatment with immunotherapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Assessment of safety by recording of adverse events

Trial Locations

Locations (1)

Healthcare Discoveries Inc.; 🇺🇸 San Antonio, Texas, United States